Naveed Janjua

Has grant

Clinical Professor

The University of British Columbia
Country flagCanada

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Naveed Janjua is a Clinical Professor at The University of British Columbia, Canada. His research focuses on public health issues related to infectious diseases, particularly Hepatitis C and the impact of COVID-19 on healthcare systems. Recent articles authored by Dr. Janjua include studies on the effects of the pandemic on Hepatitis C testing and treatment initiation, as well as healthcare utilization among myocarditis cases associated with mRNA vaccination.

Recent Grants

Grant: Close

Evaluating the impact of COVID-19 vaccine policies on vaccine equity: A multi-province comparative study

Open Date: 2022-10-01

Close Date: 2024-09-30

Grant: Close

The impact of COVID-19 and related control measures on the hepatitis C virus care cascade

Open Date: 2022-02-01

Close Date: 2024-01-31

Grant: Open

Artificial Intelligence for Public Health (AI4PH) Training Platform

Open Date: 2022-01-01

Close Date: 2027-12-31

Grant: Close

Estimating chronic hepatitis B prevalence and the undiagnosed proportion in Canada using health administrative data

Open Date: 2021-11-01

Close Date: 2022-10-31

Grant: Open

Canadian Network on Hepatitis C (CanHepC): From Discovery to Implementation

Open Date: 2021-11-01

Close Date: 2026-10-31

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Background. Data on the economic burden of chronic hepatitis C (CHC) among immigrants are limited. Our objective was to estimate the CHC-attributable mortality and healthcare costs among immigrants in Ontario, Canada. Methods. We conducted a population-based matched cohort study among immigrants diagnosed with CHC between May 31, 2003, and December 31, 2018, using linked health administrative data. Immigrants with CHC (exposed) were matched 1 : 1 to immigrants without CHC (unexposed) using a combination of hard (index date, sex, and age) and propensity-score matching. Net costs (2020 Canadian dollars) collected from the healthcare payer perspective were calculated using a phase-of-care approach and used to estimate long-term costs adjusted for survival. Results. We matched 5,575 exposed individuals with unexposed controls, achieving a balanced match. The mean age was 47 years, and 52% was male. On average, 10.5% of exposed and 3.5% of unexposed individuals died 15 years postindex (relative risk = 2.9; 95% confidence interval (CI): 2.6–3.5). The net 30-day costs per person were $88 (95% CI: 55 to 122) for the prediagnosis, $324 (95% CI: 291 to 356) for the initial phase, $1,016 (95% CI: 900 to 1,132) for the late phase, and $975 (95% CI: −25 to 1,974) for the terminal phase. The mean net healthcare cost adjusted for survival at 15 years was $90,448. Conclusions. Compared to unexposed immigrants, immigrants infected with CHC have higher mortality rates and greater healthcare costs. These findings will support the planning of HCV elimination efforts among key risk groups in the province.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (5)

Sofia Bartlett

Adjunct Professor

The University of British Columbia

CANADA
View details

William W.L. Wong

Associate Professor

University of Waterloo

CANADA
View details

Jeffrey C Kwong

University of Toronto

CANADA
View details

Nathaniel M Hawkins

The University of British Columbia

CANADA
View details

Beate Sander

University Health Network

CANADA
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.